Ask AI
ProCE Banner Events

The Evolving Role of Antibody-Drug Conjugates in Multiple Myeloma

This program focuses on the evolving role of belantamab mafodotin in relapsed/refractory multiple myeloma, including the latest efficacy and safety data, appropriate patient selection, and practical considerations for integrating belantamab mafodotin-based regimens into clinical practice.

Key Takeaways

  • Review the latest efficacy and safety data supporting belantamab mafodotin–based regimens in relapsed/refractory multiple myeloma
  • Discuss patient and disease characteristics that may inform selection within the evolving treatment landscape
  • Explore practical considerations for incorporating belantamab mafodotin into clinical practice, including ocular toxicity monitoring and management and multidisciplinary care coordination
Time and location

Tuesday, November 03, 2026

12:15 PM - 1:00 PM Eastern Time (ET)

Virtual